Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A in MSI-H or dMMR Stage IV Colorectal Cancer
NCT04895722Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 2 trial of quavonlimab in colorectal cancer (CRC), sponsored by Merck & Co.. Started Jun 2021; status: active, not recruiting.
02
Drugs
quavonlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04895722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895722.